Business, energy, technology, markets and global industry news from Business News Today

Bristol Myers Squibb

PharmaDeviceNews Bristol Myers Squibb
A representative image illustrating LB Pharmaceuticals’ LB-102 schizophrenia research as the pivotal NOVA-2 Phase 3 program advances toward an accelerated first-half 2027 readout.
Pharma & Biotech

Zai Lab just secured reimbursement for two growth medicines. Can 2027 reverse its revenue decline?

Zai Lab gains China reimbursement listings for KarXT and VYVGART Hytrulo from January 2027. See how access could reshape product growth.

Read More
Pharma & Biotech

Can Johnson & Johnson’s oral Icotyde compete with biologics in psoriatic arthritis?

Icotyde achieved 58% ACR20 in Phase 3 psoriatic arthritis, but the 400 mg dose added no benefit. Can Johnson & Johnson challenge biologics?

Read More
Representative image: A cardiologist reviews heart imaging as Cytokinetics’ $CYTK aficamten gains UK approval and NICE backing for approximately 6,600 adults with symptomatic obstructive hypertrophic cardiomyopathy.
Pharma & Biotech

Bristol Myers Squibb Camzyos franchise reaches $1.15bn as pediatric evidence expands

Camzyos maintained lower heart obstruction through 56 weeks in adolescents as Bristol Myers Squibb expands a $1.15 billion HCM franchise.

Read More
Representative image illustrating lupus drug research as Beeline Medicines reports promising Phase 2 afimetoran results, highlighting its potential as an oral treatment for systemic lupus erythematosus.
Pharma & Biotech

Afimetoran Phase 2 trial delivers significant lupus improvement as Beeline Medicines eyes pivotal studies

Explore Beeline Medicines' Phase 2 afimetoran lupus results, showing a 30-point response advantage and promising potential for an oral therapy.

Read More
An acute myeloid leukemia research setting illustrates Moleculin Biotech’s Annamycin trial and its 37% blinded remission signal in resistant AML after venetoclax treatment. Representative image.
Pharma & Biotech

Amphista Therapeutics begins first human trial of AMX-883 BRD9 degrader in acute myeloid leukemia

Amphista begins its 54-patient AMX-883 Phase 1 trial in AML and high-risk MDS. Examine the novel BRD9 mechanism, safety tests and next milestones.

Read More
Representative image: Celea Therapeutics has dosed the first patient in the Phase 3 SURPASS-IPF trial testing deupirfenidone against pirfenidone for idiopathic pulmonary fibrosis.
Pharma & Biotech

What the ALOFT-IPF results mean for Bristol Myers Squibb and pulmonary fibrosis treatment

Bristol Myers Squibb's admilparant meets Phase 3 IPF endpoint at 60 mg, but 120 mg misses. Examine efficacy, safety and FDA prospects.

Read More
Tract Bio’s TP101 and stemECHO research targets drug-resistant cancer stem cells through preclinical combination testing and functional precision medicine screening. Representative image.
Pharma & Biotech

Bristol Myers Squibb’s $4.1bn RayzeBio acquisition delivers clinical milestone

Bristol Myers Squibb's RYZ101 meets its Phase 3 endpoint after lutetium-177 treatment, advancing alpha radiopharmaceutical development.

Read More
Editorial infographic illustrating GSK’s expanded AI drug discovery collaboration with Chai Discovery, featuring molecular protein-binding visuals, wet-lab testing, and key highlights on early binding success and unproven clinical and commercial outcomes.
Pharma & Biotech

Why GSK’s wet-lab validation gives Chai Discovery a stronger pharmaceutical industry foothold

GSK expands Chai Discovery AI collaboration after wet-lab success. See what the binding results establish and what remains unproven.

Read More
Infographic showing Akeso’s Phase III cadonilimab trial in colon cancer, with 386 patients planned and recurrence outcomes highlighted as a central study focus.
Pharma & Biotech

Cadonilimab delivered 84.6% complete responses in an earlier study. Can Akeso prove lasting benefit?

Akeso starts Phase III cadonilimab testing in colon cancer, with 386 patients planned and recurrence outcomes central to its clinical strategy.

Read More
Bristol Myers Squibb is defending its multibillion-dollar Opdivo immunotherapy franchise as Amgen develops a proposed nivolumab biosimilar ahead of approaching United States patent expiry. Representative image.
Pharma & Biotech

Bristol Myers Squibb sues Amgen over Opdivo biosimilar as $10bn franchise nears patent cliff

Bristol Myers Squibb and Ono Pharmaceutical are suing Amgen over seven patents tied to its proposed Opdivo biosimilar ABP 206, opening an important legal battle around a cancer drug that generated more than $10 billion in 2025.

Read More